PharmaEssentia stock
Price history
+156.62% over the period1 year: from $428.66 (November 20, 2025) to $1,100.00 (November 20, 2026), +156.62%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 20, 2026 | $1,100.00 |
| October 30, 2026 | $1,190.00 |
| September 30, 2026 | $1,215.00 |
| August 31, 2026 | $1,395.00 |
| July 31, 2026 | $1,060.00 |
| June 30, 2026 | $1,207.99 |
| May 29, 2026 | $838.38 |
| April 30, 2026 | $595.88 |
| March 31, 2026 | $540.89 |
| February 26, 2026 | $652.68 |
| January 30, 2026 | $694.15 |
| December 31, 2025 | $423.70 |
| November 28, 2025 | $465.17 |
| November 20, 2025 | $428.66 |
At a glance
The company
Biopharmaceutical company developing specialty pharmaceutical products and treatments for blood disorders and cancers
Latest results
Quarter to September 30, 2026 · EPS $7.08 (estimate $6.81)
TickerLandia's take on PharmaEssentia
- Pricier than similar companies: trailing 12-month P/E 74 vs 29 (+158%) in a group of 11.
- Strong point: Growth (97/100 in its group). Weak point: Earnings stability (5/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−33.13% from the 52-week high
Analysts · 8 analysts
Average target$1,437.27+30.66% vs. price
Buy 7 · Hold 1 · Sell 0 · Buy
TickerLandia Fingerprint: PharmaEssentia
Compared with similar companies: very high growth, very low earnings stability, and very high profitability.
Financials and price compared with 39 companies in the drug manufacturers - specialty & generic industry, worldwide. Momentum and risk compared with 1,074 Asia-Pacific stocks.
Pricevery high89
How much it costs relative to what it produces.
Metric Value Position in group P/E (trailing 12 months) 74.1 84 Forward P/E 32.1 79 EV/EBITDA 45.7 90 Price/book 14.0 94 Price/sales 24.9 99 Profitabilityvery high94
How much it earns on revenue and capital.
Metric Value Position in group Gross margin 90.9% 99 Operating margin 38.4% 96 Net margin 36.8% 91 ROE 23.3% 88 ROA 12.9% 94 Earnings stabilityvery low5
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 190.3% 1 Loss-making yearscounts in reverse: lower means more earnings stability 3 of 5 annual reports 9 Growthvery high97
How fast revenue and earnings are growing.
Metric Value Position in group Average revenue growth (3 years) +75.71% 99 Revenue growth (year over year) +90.30% 99 Earnings growth (year over year) +203.47% 93 Financial strengthvery high89
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Net debt/EBITDAcounts in reverse: lower means more financial strength · more cash than debt −4.31 93 Interest coverage 193.0 86 Debt/equitycounts in reverse: lower means more financial strength 0.03 85 Current ratio 5.28 94 Dividendvery low7
How much it returns to shareholders, and for how long.
Metric Value Position in group Consecutive dividend years 2 years 9 Dividend yield 0.1% 8 Payout ratio 6.8% 5 Market momentumvery strong93
How the stock has moved compared with the market.
Metric Value Position in group Distance from 200-day average +12.88% 87 1-year return +156.62% 99 Riskhigh61
How much the price swings.
Metric Value Position in group Volatility (60 days) 59.4% 79 Maximum drawdown (12 months) 30.6% 42
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
PharmaEssentia is pricier than similar companies
PharmaEssentia's P/E (trailing 12 months): 74.1, +158% against the median of a group of 11 similar companies (28.7).
Compared with 11 similar companies
| Metric | PharmaEssentia | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 74.1 | High | |
| Forward P/E | 29.3 | High | |
| Operating margin | 38.4% | High | |
| ROE | 23.3% | High | |
| Debt/equity | 0.03 | Middle |
Grey band: the middle half of the group; tick: the median; dot: PharmaEssentia. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
$6.86B
Latest quarter · Q2 2026
Net income
$2.53B
Latest quarter · Q2 2026
Quarterly net margin
36.9%
Latest quarter · Q2 2026
Numbers and valuation
Full valuation- Market cap
- $526.33B
- P/E
- 74.1
- EPS
- $21.98
- Volume
- 5.63M
- Daily trading
- €119.22M
- Dividend yield
- 0.14%
- Last ex-dividend on July 9, 2026
How PharmaEssentia is changing
All resultsRevenue grew 94.8% a year on average over the last 5 years
Operating margin rose from −70.4% to 31.5%
Less cash than profit: free cash flow equal to 41% of net income
Returns
PharmaEssentia returns with dividends
$1,000 invested in PharmaEssentia 5 years ago, on November 22, 2021, would be worth $7,576 today: +657.58% in total, +50.00% per year. This is the price return only: dividends are excluded.
| Period | PharmaEssentia | $1,000 becomes |
|---|---|---|
| 1 month | −4.76% | $952 |
| 6 months | +54.65% | $1,547 |
| Year to date | +159.62% | $2,596 |
| 1 year | +156.91% | $2,569 |
| 3 years | +275.10% | $3,751 |
| 5 years | +657.58% | $7,576 |
| 10 years | +634.96% | $7,350 |
From 1 year up with dividends reinvested, before taxes; under a year price only. Calculate your investment
The chart in detail
PharmaEssentia: technical analysis
PharmaEssentia shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 30.6% below its all-time closing high ($1,585.00, August 26, 2026).
- Trend
- No clear trend
- RSI (14 sessions)
- 38
- Between 30 and 70
- vs 200-session average
- +12.88%
Active signals
The last session opened more than 3% below the previous close.
Support and resistance
Price areas where PharmaEssentia has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistance$1,290.00+17.27%2 touches, last on October 16, 2026
- Resistance$1,240.00+12.73%2 touches, last on October 1, 2026
- Resistance$1,147.50+4.32%6 touches, last on October 27, 2026
- Last price$1,100.00
- Support$900.59−18.13%2 touches, last on June 10, 2026
- Support$696.85−36.65%2 touches, last on February 26, 2026
- Support$605.44−44.96%5 touches, last on April 20, 2026
Volatility and risk
- Volatility (60 sessions, annualised)
- 59.4%
- Largest fall in the last year
- −30.60%
Close of November 20, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
PharmaEssentia: seasonality
Average monthly price change over 13 years
Over the last 13 years, the strongest month for PharmaEssentia has been November: +20.67% on average, positive in 9 years out of 12. The weakest has been March: −8.69% on average, positive in 3 years out of 12.
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +3.04% | −2.23% | 5 of 12 |
| February | +3.74% | +2.92% | 7 of 12 |
| March | −8.69% | −6.00% | 3 of 12 |
| April | −2.13% | −4.85% | 4 of 13 |
| May | +8.66% | −1.66% | 6 of 13 |
| June | +12.02% | +9.60% | 9 of 13 |
| July | −0.77% | +0.70% | 7 of 13 |
| August | +1.32% | +0.10% | 7 of 13 |
| September | −1.15% | −4.39% | 5 of 13 |
| October | −4.74% | −3.30% | 4 of 13 |
| November | +20.67% | +9.38% | 9 of 12 |
| December | +2.44% | −2.36% | 5 of 12 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
PharmaEssentia and its competitors
With revenue of TWD 15.6 billion in the fiscal year ended December 2025, PharmaEssentia Corporation develops specialty pharmaceutical reagents, active pharmaceutical ingredients and new drugs, with activities in the Americas, Europe, Asia and Taiwan. Its main product, BESREMi, is used to treat polycythemia vera and essential thrombocythemia, and the company also works on treatments for adult T-cell leukemia. Its pipeline spans cancer and immunology programs, including PEG-IL-2, PD-1-IL-2v and TCR-T therapies for solid tumors.
- Headquarters
- Taipei, Taiwan
- Employees
- 131
- Founded
- 1990
- Chief executive
- Ko-Chung Lin
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| PharmaEssentia6446 | $15.94B | 38.4% | 74.1 | +54.65% |
| Shionogi4507 | $16.75B | 31.6% | 11.2 | +2.83% |
| Yunnan Baiyao Group000538 | $15.07B | 11.2% | 19.4 | +11.07% |
| Laurus LabsLAURUSLABS | $14.13B | 24.1% | 97.8 | +68.58% |
| Torrent PharmaceuticalsTORNTPHARM | $19.25B | 22.2% | 79.2 | +5.88% |
| Zydus LifesciencesZYDUSLIFE | $12.92B | 17.2% | 28.7 | +15.29% |
Same industry or related industries, similar size. Compare PharmaEssentia with its competitors · Full profile
